Cell therapy for EBV-positive nasopharyngeal cancer after standard treatment fails
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your nasopharyngeal cancer must be confirmed and test positive for the Epstein-Barr virus (EBV).
- Your cancer must have come back locally, spread to other parts of the body, or be in an advanced stage where standard treatments no longer work.
- You should be able to do everyday activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, heart, and clotting function need to be within safe ranges.
- You cannot be pregnant, breastfeeding, or planning a pregnancy soon, and you must not have active infections like hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This study tests whether adding natural killer (NK) cells, which are immune cells that can attack cancer, to the usual chemotherapy and radiation treatment helps people with advanced nasopharyngeal cancer. It aims to improve treatment outcomes for patients with high-risk disease.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This trial tests a new treatment (KSD-101) for nasopharyngeal cancer that has not responded to standard therapies. It aims to see if this treatment can help when other options have failed.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.